.Property manager TPG, which has sustained biotechs like Sionna Therapies as well as Santa Ana Bio, ...
.Merck & Co.'s TIGIT plan has endured another obstacle. Months after shuttering a phase 3 cancer ...
.After a year defined by pipeline hairstyles, the shift of its own chief executive officer and cutba...
.Cullinan Therapeutics was actually made an impression on good enough along with Harbour BioMed's bi...
.Within this week's incident of "The Best Pipe," our team are actually diving right into Intense Bio...
.The confetti is still flying coming from Eli Lilly's gathering celebrating the approval of Alzheime...
.Welcome to today's Chutes & Ladders, our summary of considerable leadership hirings, shootings a...
.Adhering to a bad revealing for Lykos Therapeutics' MDMA applicant for post-traumatic stress disord...
.AN2 Therapies is rethinking its own company in feedback to poor midphase records, promising to lay ...
.Merck & Co. is spending $700 million in advance to challenge Amgen in a blood stream cancer mark...